Journal
CANCER RESEARCH
Volume 69, Issue 7, Pages 2699-2703Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-08-4359
Keywords
-
Categories
Funding
- NCI [CA 127729]
Ask authors/readers for more resources
The lack of treatment for worried well patients with high-grade prostatic intraepithelial neoplasia combined with issues of recurrence and hormone resistance in pros a e cancer survivors remains a major public health obstacle. The long latency of prostate cancer development provides an ample opportunity to intervene with mechanistically based chemopreventive agents at various stages of disease progression. Our rationale for selenium intervention is based on current mechanistic knowledge derived solely from preclinical investigations. Clearly, there is sufficient scientific support for its entry into current clinical trials, the outcome of which will be highly valuable in assessing whether selenium can be recommended for cancer survivors. [Cancer Res 2009;69(7):2699-703]
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available